Marshall Wace
HRTX icon

Marshall Wace’s Heron Therapeutics HRTX Stock Holding History

Marshall Wace’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Buy
+2,354,193
New +$1.89M ﹤0.01% 2184
2025
Q4 		– Sell
-1,308,861
Closed -$1.65M – 3175
2025
Q3 		$1.65M Sell
1,308,861
-1,585,211
-55% -$2.51M ﹤0.01% 1712
2025
Q2 		$5.99M Buy
2,894,072
+1,639,376
+131% +$3.35M 0.01% 1056
2025
Q1 		$2.76M Buy
1,254,696
+237,157
+23% +$460K ﹤0.01% 1328
2024
Q4 		$1.56M Sell
1,017,539
-698,006
-41% -$1.13M ﹤0.01% 1547
2024
Q3 		$3.41M Sell
1,715,545
-45,506
-3% -$109K ﹤0.01% 1149
2024
Q2 		$6.16M Buy
1,761,051
+1,266,697
+256% +$3.89M 0.01% 923
2024
Q1 		$1.37M Buy
+494,354
New +$1.24M ﹤0.01% 1525
2019
Q3 		– Sell
-68,904
Closed -$1.28M – 1782
2019
Q2 		$1.28M Buy
68,904
+68,701
+33,843% +$1.37M 0.01% 872
2019
Q1 		$5K Sell
203
-20,843
-99% -$546K ﹤0.01% 1648
2018
Q4 		$546K Sell
21,046
-8,864
-30% -$244K 0.01% 1069
2018
Q3 		$947K Buy
+29,910
New +$1.11M 0.01% 823
2018
Q2 		– Sell
-12,100
Closed -$334K – 755
2018
Q1 		$334K Buy
+12,100
New +$274K 0.01% 452

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Marshall Wace's HRTX Position: Q2 2026 in Review

Marshall Wace opened a new position in Heron Therapeutics (HRTX) in Q2 2026: 2,354,193 shares worth $1.01M. The stake represents ﹤0.01% of the portfolio and ranks #2184 among its holdings. This is a return to the name: Marshall Wace previously reported a position in HRTX as recently as Q3 2025.

Marshall Wace first reported a position in HRTX in Q1 2018 and has held it in 13 quarters since. The position peaked at $6.16M in Q2 2024. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Marshall Wace held 2,354,193 shares of Heron Therapeutics worth $1.01M as of Q2 2026.
  • Heron Therapeutics was a new Marshall Wace position in Q2 2026.
  • Heron Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2184 holding.
  • Marshall Wace first reported a position in Heron Therapeutics in Q1 2018 and has held it in 13 quarters since.
  • Marshall Wace's Heron Therapeutics position peaked at $6.16M in Q2 2024.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.